Cargando…

Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis

OBJECTIVE: Anti–topoisomerase I (anti–topo I) autoantibodies in systemic sclerosis (SSc) are associated with diffuse skin involvement and interstitial lung fibrosis. Thus far, however, the relationship between anti–topo I antibody response and disease course has not yet been fully evaluated. This st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boonstra, Maaike, Bakker, Jaap A., Grummels, Annette, Ninaber, Maarten K., Ajmone Marsan, Nina, Wortel, Corrie M., Huizinga, Tom W. J., Jordan, Suzana, Hoffman‐Vold, Anna‐Maria, Distler, Oliver, Toes, René E. M., Scherer, Hans Ulrich, de Vries‐Bouwstra, Jeska K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702063/ https://www.ncbi.nlm.nih.gov/pubmed/32840062 http://dx.doi.org/10.1002/art.41403

Ejemplares similares

Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis
por: Wortel, Corrie M, et al.
Publicado: (2023)

Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies
por: Liem, Sophie I E, et al.
Publicado: (2023)

Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

New risk model is able to identify patients with a low risk of progression in systemic sclerosis
por: van Leeuwen, Nina Marijn, et al.
Publicado: (2021)

Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes
por: Gegenava, Tea, et al.
Publicado: (2023)

Evolution of Systemic Sclerosis–Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide
por: Ciaffi, Jacopo, et al.
Publicado: (2022)

Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort
por: Hanke, Katharina, et al.
Publicado: (2009)

Structural studies of type I topoisomerases
por: Baker, Nicole M., et al.
Publicado: (2009)

Bacterial topoisomerase I and topoisomerase III relax supercoiled DNA via distinct pathways
por: Terekhova, Ksenia, et al.
Publicado: (2012)

A prediction model for progressive disease in systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2015)

Oral manifestations of Systemic Sclerosis and Correlation with anti-Topoisomerase I Antibodies (SCL-70)
por: Bajraktari, Ismet H., et al.
Publicado: (2015)

Mangiferin-Loaded Polymeric Nanoparticles: Optical Characterization, Effect of Anti-topoisomerase I, and Cytotoxicity
por: Razura-Carmona, Francisco Fabian, et al.
Publicado: (2019)

The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA–topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts
por: Dexheimer, Thomas S., et al.
Publicado: (2008)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

Topoisomerase I in Human Disease Pathogenesis and Treatments
por: Li, Min, et al.
Publicado: (2016)

QSAR Modeling on Benzo[c]phenanthridine Analogues as Topoisomerase I Inhibitors and Anti-cancer Agents
por: Thai, Khac-Minh, et al.
Publicado: (2012)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

New Topoisomerase I mutations are associated with resistance to camptothecin
por: Gongora, Céline, et al.
Publicado: (2011)

Adaptation of topoisomerase I paralogs to nuclear and mitochondrial DNA
por: Rosa, Ilaria Dalla, et al.
Publicado: (2009)

Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I
por: Sobek, Stefan, et al.
Publicado: (2013)

Autoregulation of topoisomerase I expression by supercoiling sensitive transcription
por: Ahmed, Wareed, et al.
Publicado: (2016)

Immunodetection of human topoisomerase I-DNA covalent complexes
por: Patel, Anand G., et al.
Publicado: (2016)

Bulge oligonucleotide as an inhibitory agent of bacterial topoisomerase I
por: Yang, Zhaoqi, et al.
Publicado: (2017)

Novel bivalent securinine mimetics as topoisomerase I inhibitors
por: Hou, Wen, et al.
Publicado: (2017)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

‘LeishMan’ topoisomerase I: an ideal chimera for unraveling the role of the small subunit of unusual bi-subunit topoisomerase I from Leishmania donovani
por: Ganguly, Agneyo, et al.
Publicado: (2006)

CK2-Mediated Hyperphosphorylation of Topoisomerase I Targets Serine 506, Enhances Topoisomerase I–DNA Binding, and Increases Cellular Camptothecin Sensitivity
por: Bandyopadhyay, Keya, et al.
Publicado: (2012)

Anti-DNA topoisomerase I autoantibodies bind directly to the cell surface of fibroblasts in patients with systemic sclerosis
por: Senécal, J-L, et al.
Publicado: (2004)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II
por: Xu, Huanli, et al.
Publicado: (2016)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

Systemic sclerosis: state of the art on clinical practice guidelines
por: Smith, Vanessa, et al.
Publicado: (2018)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_8n1g5jtvmflrblpdp6k4kc9dsd